Lv2
168 积分 2022-04-14 加入
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
2个月前
已完结
Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer
5个月前
已完结
Prediction of Ischemic Stroke Functional Outcomes from Acute-Phase Noncontrast CT and Clinical Information
5个月前
已完结
A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study
9个月前
已完结
Real-World Experience with177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval
10个月前
已关闭
Development of a Visually Calculated SUVmean(HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to177Lu-PSMA Therapy: Comparison with Quantitative SUVmeanand Patient Outcomes
10个月前
已关闭
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial
10个月前
已完结
Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers
1年前
已完结
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects
1年前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
1年前
已完结
皖公网安备34019202002308
